Mammary Cell News Volume 4.17 | May 3 2012

LABORATORY RESEARCH

Acetylated STAT3 Is Crucial for Methylation of Tumor-Suppressor Gene Promoters and Inhibition by Resveratrol Results in Demethylation
Researchers showed reduction of acetylated STAT3 in triple-negative breast cancer cells leads to demethylation and activation of the estrogen receptor-α gene, sensitizing tumor cells to antiestrogens. [Proc Natl Acad Sci USA] Full Article

AIB1:ERalpha Transcriptional Activity Is Selectively Enhanced in AI-Resistant Breast Cancer Cells
Researchers investigated the role of aromatase inhibitor B1 (AIB1) in the deregulation of ER target genes occurring as a consequence of AI resistance using tissue microarrays of breast cancer patient tissue and cell line models of resistance to the AI letrozole. [Clin Cancer Res] Abstract

MGMT Inhibition Restores ERα Functional Sensitivity to Anti-Estrogen Therapy
Results suggested that MGMT inhibition leads to growth inhibition of tamoxifen resistant breast cancer in vitro and in vivo and re-sensitizes tamoxifen resistant breast cancer cells to anti-estrogen therapy. [Mol Med]
Full Article

Suppressor of Cytokine Signaling 3 Inhibits Breast Tumor Kinase Activation of STAT3
Investigators showed that suppressor of cytokine signaling 3 (SOCS3) can inhibit the unconventional target, breast tumor kinase (Brk). Investigation of the mechanism by which SOCS3 inhibits Brk revealed the SOCS3 protein binds to Brk primarily via its SH2 domain, and its main inhibitory effect is mediated by the SOCS3 kinase inhibitory region. [J Biol Chem] Full Article

DNA Damage Induces NF-κB-Dependent MicroRNA-21 Upregulation and Promotes Breast Cancer Cell Invasion
Researchers showed that chemotherapeutic drug-induced NF-κB activation promotes breast cancer cell migration and invasion. [J Biol Chem] Full Article

Identification of NOG as a Specific Breast Cancer Bone Metastasis-Supporting Gene
Scientists provided molecular evidence showing that the bone morphogenetic protein inhibitor, NOG, provide metastatic breast cancer cells with the ability to colonize the bone. [J Biol Chem] Full Article

Spontaneous Formation of Tumorigenic Hybrids between Breast Cancer and Multipotent Stromal Cells Is a Source of Tumor Heterogeneity
Researchers reported the spontaneous in vitro formation of heterotypic hybrids between human bone marrow-derived multipotent stromal cells and two different breast carcinoma cell lines. [Am J Pathol] Abstract

Gene-Specific Patterns of Coregulator Requirements by Estrogen Receptor-α in Breast Cancer Cells
Researchers used RNA interference to demonstrate dramatic differences in requirements of ten different coregulators for estrogen-regulated expression of six different genes, including progesterone receptor and the well-studied TFF1 gene in MCF-7 breast cancer cells. [Mol Endocrinol] Abstract

Co-Expression of α9β1 Integrin and VEGF-D Confers Lymphatic Metastatic Ability to a Human Breast Cancer Cell Line MDA-MB-468LN
Investigators concluded that the differential capacity for VEGF-D production and α9β1 integrin expression by MDA-MB-468LN cells jointly contributed to their lymphatic metastatic phenotype. [PLoS One] Full Article

CLINICAL RESEARCH

Accelerated Partial Breast Irradiation Using Only Intraoperative Electron Radiation Therapy in Early Stage Breast Cancer
Scientists reported the results of a single-institution, phase II trial of accelerated partial breast irradiation using a single dose of intraoperative electron radiation therapy in patients with low-risk early stage breast cancer. [Int J Radiat Oncol Biol Phys] Abstract

Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial
To evaluate the safety and efficacy of Tien-Hsien Liquid Practical in patients with refractory metastatic breast cancer, researchers performed a randomized, double-blind, placebo-controlled, parallel-group, phase IIa pilot trial. [Evid Based Complement Alternat Med] Full Article

Baylor College of Medicine Receives Department of Defense Awards to Study New Therapeutic Targets in Breast Cancer
Researchers recently received Department of Defense Breast Cancer Research Program awards to study new therapeutic targets based on the genomic changes that drive tumor formation. [Baylor College of Medicine] Press Release

Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a First-in-Class, Anti-Cancer Compound
Lixte Biotechnology Holdings, Inc. announced the submission of an IND application to the Food and Drug Administration (FDA) to conduct a Phase I trial of its lead, anti-cancer compound, LB-100. [PR Newswire] Press Release

Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
Leica Biosystems announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration (FDA) for the Leica Bond Oracle HER2 (Human Epidermal Growth Factor Receptor 2) immunohistochemical (IHC) System with the Leica BOND-MAX. [Leica Biosystems] Press Release

Chinese Publishers Vow to Cleanse Journals
The China Association for Science and Technology in Beijing has taken the lead among the country’s publishers in trying to clamp down on academic misconduct. [The China Association for Science and Technology, China] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Third International Symposium on Breast Cancer Prevention: Models for Breast Cancer Prevention from Innovation to Action
October 10-12, 2012
West Lafayette, United States

NEW 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 6-9, 2012
Dublin, Ireland

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoctoral Position – Breast Cancer Biology (Bellvitge Institute for Biomedical Research)

Postdoc Positions – Molecular Cancer Biology (Baylor College of Medicine)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.